# Callio Therapeutics funding rounds and investors

As of 14 Oct 2026, Callio Therapeutics has raised $187M across 1 verified round on record; latest: $187.0 million Series A led by Frazier Life Sciences, announced 3 Mar 2025.

Dual-payload antibody-drug conjugates (ADCs) for cancer treatment.

Website: https://calliotx.com  
Headquarters: Seattle and Singapore  
Page: https://fireround.dev/companies/calliotx.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2025-03-03 | Series A | $187.0 million | Frazier Life Sciences | ClavystBio, EDBI (Singapore), Jeito Capital, Norwest, Novo Holdings A/S, Omega Funds, Platanus Ventures, Pureos Bioventures, Seeds | [prnewswire.com](https://www.prnewswire.com/news-releases/callio-therapeutics-launches-with-us187-million-series-a-to-advance-multi-payload-antibody-drug-conjugate-platform-through-clinical-proof-of-concept-302388161.html) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.